Table 2.
Sites of manifestation, symptoms, complications, and coexisting conditions after 1 year of follow-up from the SSc diagnosis date from medical claims data in US MarketScan (see Supplementary Appendix 2 for grouping of categories)
| Condition or site of manifestation | Patients, n (%) N = 6852a |
|---|---|
| Lung | 2089 (30.5) |
| Heart | 1189 (17.4) |
| Gastrointestinal tract | 1532 (22.4) |
| Musculoskeletal | 1102 (16.1) |
| Infections | 1035 (15.1) |
| Overlap syndrome | 956 (14.0) |
| Fatigue | 721 (10.5) |
| Skin | 217 (3.2) |
| Headache | 355 (5.2) |
| Backache | 329 (4.8) |
| Dizziness | 321 (4.7) |
| Abnormal blood chemistry | 268 (3.9) |
| Anemia | 174 (2.5) |
| Kidney | 156 (2.3) |
| Endocrine | 89 (1.3) |
| Depression or anxiety | 84 (1.2) |
| Asthma | 73 (1.1) |
| Malignancy (all) | 14 (0.2) |
| Benign neoplasm of colon | 14 (0.2) |
| Osteoporosis | 3 (0.04) |
| Neoplasm of uncertain behavior of skin | 1 (0.01) |
All data are number (%) of patients with condition
SSc systemic sclerosis
aPatients with valid treatments of interest (defined as at least 1 day’s supply)